Canaccord Genuity Downgrades Teva Pharma (TEVA) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Teva Pharmaceutical (TEVA) Misses Q4 EPS by 1c
February 7, 2013 7:18 AM ESTTeva Pharmaceutical (NYSE: TEVA) reported Q4 EPS of $1.32, $0.01 worse than the analyst estimate of $1.33. Revenue for the quarter came in at $5.2 billion versus the consensus estimate of $5.26 billion.
For earnings history and earnings-related data on Teva Pharmaceutical (TEVA) click here.... More
